Patients
tumors
TUMORS
This study was a multicenter, prospective, open-label, single-arm, phase II clinical trial that recruited patients through central registration. Women (age: 20–70 years) with histologically proven operable BC (T1c-T3N0-2M0, stages I–IIIB) were enrolled. Patients with a history of any previous therapy were excluded. All tumors were tested for estrogen receptor (ER), progesterone receptor (PgR), HER2, and Ki67 expression by immunohistochemistry (IHC) [